StockData
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

CorMedix Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)

Close on Oct 19, 2026

Market cap
$682.50M
P/E (TTM)
3.6
Dividend yield
–

Earnings

Next report expected Oct 19, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026Before market open$101.90M$0.29–
Q1 FY2026
Ended Mar 31, 2026
May 14, 2026Before market open$127.40M$0.43–
Q4 FY2025
Ended Dec 31, 2025
Jan 8, 2026Before market open$127.00M––
Q3 FY2025
Ended Sep 30, 2025
Oct 20, 2025Before market open$100.00M––
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open$39.70M$0.28–
Q1 FY2025
Ended Mar 31, 2025
Apr 8, 2025Before market open$39.00M––
Q4 FY2024
Ended Dec 31, 2024
Jan 7, 2025Before market open$31.00M––
Q3 FY2024
Ended Sep 30, 2024
Oct 30, 2024Before market open$11.50M$-0.05–
Q2 FY2024
Ended Jun 30, 2024
Aug 14, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Mar 12, 2024Before market open–––

Company guidance

Outlook given with results on Aug 13, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
adjusted EBITDAnon-GAAPfull-year$125.00M to $140.00MRaised
Cash OpExfull-year$145.00M to $155.00MRaised
consolidated revenuefull-year 2026$325.00M to $345.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements CorMedix filed with the SEC